Here are three things to know.
- Merck’s biosimilar, Lusdana Nexvue, is an insulin injection available in a pre-filled dosing device.
- Sanofi sued Merck in September, claiming Lusdana infringed on Lantus’ patent rights.
- The lawsuit prevents the FDA from issuing a final approval for Lusdana Nexvue for up to 30 months or until a court rules in favor of Merck, whichever occurs sooner.
More articles on supply chain:
Bloomberg: FedEx’s TNT ‘may never fully recover’ from Petya attack
5 must-reads for supply chain leaders this week
Cardinal Health puts $1.5B China unit up for sale, sources say
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
